Prosecution Insights
Last updated: November 04, 2026
Application No. 18/288,506

APPLICATION OF CRMP2 AND ANTI-CRMP2 ANTIBODY

Final Rejection §103§112
Filed
Oct 26, 2023
Priority
Apr 27, 2021 — CN 202110461611.6 +1 more
Examiner
VOLKOV, ALEXANDER ALEXANDROVIC
Art Unit
1677
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Guangzhou Southmed Kindstar Biotechnology Co. Ltd.
OA Round
2 (Final)
30%
Grant Probability
At Risk
3-4
OA Rounds
1y 0m
Est. Remaining
51%
With Interview

Examiner Intelligence

Grants only 30% of cases
30%
Career Allowance Rate
28 granted / 95 resolved
-30.5% vs TC avg
Strong +22% interview lift
Without
With
+21.5%
Interview Lift
resolved cases with interview
Typical timeline
4y 0m
Avg Prosecution
35 currently pending
Career history
137
Total Applications
across all art units

Statute-Specific Performance

§101
8.9%
-31.1% vs TC avg
§103
37.8%
-2.2% vs TC avg
§102
12.3%
-27.7% vs TC avg
§112
31.8%
-8.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 95 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims Claims 11-19 were pending. Claims 11 and 13 are amended. Claims 14-19 are cancelled. Claims 11-13 are examined herein. Withdrawn Rejections The objection to the specification is withdrawn in view of specification amendments. The objections to claims 11 and 13 are withdrawn in view of claims amendments. The rejections of claim 11 under 35 U.S.C. 102 and claims 12-13 under 35 U.S.C. 103 are withdrawn in view of claim 11 amendments. The rejection of claims 14-19 is withdrawn in view of claims cancellation. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL. —The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 11-13 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Amended claim 11 specifically excludes phosphorylated CRMP2. However, the specification fails to disclose non-phosphorylated and phosphorylated forms of CRMP2 as distinct forms of CRMP2 for detecting anti-CRMP2 antibodies. Accordingly, the specification fails to disclose detecting anti-CRMP2 antibodies having distinct specificities to non-phosphorylated and phosphorylated forms of CRMP2. Prior art is silent on detecting anti-CRMP2 antibodies having distinct specificities to non-phosphorylated and phosphorylated forms of CRMP2. “Any negative limitation or exclusionary proviso must have basis in the original disclosure. If alternative elements are positively recited in the specification, they may be explicitly excluded in the claims. The mere absence of a positive recitation is not basis for an exclusion. Any claim containing a negative limitation which does not have basis in the original disclosure should be rejected under 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement.” MPEP 2173.05(i). The specification as originally filed does not provide support for claim 11 as amended. There is no literal basis in the specification for this limitation. This is a new matter rejection. Therefore, based on the above findings, one of ordinary skill in the art would conclude that Applicant did not have possession of the claimed invention. Response to Arguments Applicant's arguments filed July 21, 2026 have been fully considered. Claim 11 amendments overcome the rejection of claim 11 under 35 U.S.C. 102 and claims 12-13 under 35 U.S.C. 103. Therefore, the rejections are withdrawn. Other arguments are moot because the rejections are withdrawn. Subject Matter Free of the Prior Art Claims 11-13 are free of the prior art. A method for detecting anti-CRMP2 (collapsin response mediator protein 2) antibodies, wherein the CRMP2 does not include phosphorylated CRMP2 are not known in the art. The prior art neither teaches nor suggests excluding phosphorylated CRMP2 from detection assays of anti-CRMP2 antibodies. The closest prior art: Adamus et al. (IDS; BMC Ophthalmol. 2013 Sep 25; 13:48) teach recognition of CRMP2 protein by patient autoantibodies (Abstract. Results) but fail to tech that CRMP2 protein is non-phosphorylated. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alexander Volkov whose telephone number is (571) 272-1899. The examiner can normally be reached M-F 9:00AM-5:00PM (EST). If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bao-Thuy Nguyen can be reached on (571) 272-0824. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from Patent Center. Status information for published applications may be obtained from Patent Center. Status information for unpublished applications is available through Patent Center for authorized users only. Should you have questions about access to Patent Center, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) Form at https://www.uspto.gov/patents/uspto-automated- interview-request-air-form. /ALEXANDER ALEXANDROVIC VOLKOV/ Examiner, Art Unit 1677 /REBECCA M GIERE/Primary Examiner, Art Unit 1677
Read full office action

Prosecution Timeline

Oct 26, 2023
Application Filed
Apr 21, 2026
Non-Final Rejection mailed — §103, §112
Jul 21, 2026
Response Filed
Oct 19, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12782361
IDENTIFICATION AND MONITORING OF ACID HYDROLYSIS PRODUCTS OF IMMUNOGLOBULIN HEAVY CHAINS
6y 7m to grant Granted Nov 03, 2026
Patent 12768842
MASS SPECTROMETRY CONTROLS
3y 11m to grant Granted Oct 20, 2026
Patent 12742786
ASSAY AND KIT FOR LIVE ANTIGEN DETECTION AND MONITORING OF NEUROCYSTICERCOSIS
3y 12m to grant Granted Sep 22, 2026
Patent 12669512
PROTEIN DIAGNOSTIC BIOMARKER FOR SEVERE DRUG ERUPTION
3y 5m to grant Granted Jun 30, 2026
Patent 12656339
METHODS, REAGENTS, AND SUBSTRATES FOR DETECTING TARGET ANALYTES
5y 3m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
30%
Grant Probability
51%
With Interview (+21.5%)
4y 0m (~1y 0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 95 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month